Member Info for VP007

Just reading an article from 30th September and came across this:

https://www.blackfordanalysis.com/category/blackford-curated-marketplace/

“Visualization and analytical solutions developer Imaging Biometrics revealed that IB Neuro’s dynamic susceptibility contrast (DSC) perfusion approach was recently featured in Neuro Oncology as the national recommended standard, as determined by the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition. The company also told us that its software has recently been installed at the Keck Medical Center at USC, and that several veterinary groups are now also using IB software to help treat our furry friends!”

Does anyone know what vetinary groups are now using IB software?

Really hoping we can sustain the rise into tomorrow. My average is 16.2p so have been heavily down.

For anyone interested, here is the FDA approval documentation for the LSN software.

https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201092.pdf

Hi All,

I thought it would be good to start a thread on the positive news flow forecast for this company.

Please add to this list with any other research or upcoming events.

A starter for 10...

- Further LSN deals (Q4 2020)
- LSN CE Mark (Q4 2020)
- Gad Free Imaging update (Q4??)
- StoneChecker Version 2.0 launch (Q4 2020)
- Commercialisation of IB Neuro, IB DCE, IB Delta T1 Maps, IB Diffusion via arterys marketplace (Q4 2020)
- IB Cad - 18 months development (from July 2020)

Let’s get the research going!

VP

Hi Oxford,

Many thanks.

I don’t think these are approved yet as the IPSUM website is showing these at a status of “Pending”.

I am not sure on what the standard UK approval times are, but at least we can be sure they have been lodged and are within the approval process.

Hi All,

I have been monitoring Synairgens UK Patent application statuses and it seems a new Patent for COPD is now showing within the October journal as below:

Date Application
Number

02 September 2020
(Journal 6850) GB2011216.5 Applicant: Synairgen Research Ltd
Title: Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients
Date Lodged: 20 July 2020

02 September 2020
(Journal 6850) GB2011284.3 Applicant: Synairgen Research Ltd
Title: Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
Date Lodged: 21 July 2020

21 October 2020
(Journal 6857) GB2014114.9 Applicant: Synairgen Research Ltd
Title: Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
Date Lodged: 8 September 2020

I think I could have summarised that whole briefing in 3 simple bullet points....1) we learnt a lot in wave 1....2) we won’t tell you what we’ve learnt but we will apply it to wave 2.....3) we are not sure what impact it will have, but we may figure it out in wave 3

I think they would make Synairgen do the hard yards first e.g. build the manufacturing infrastructure and get the necessary approvals (following successful trial).

Great research WedME!

We can all see the benefits and value of this drug, but unfortunately it appears that our UK Government is not on the same page.

It is going to take something big for the Government to U-Turn on its Oxford COVID Vaccine.

Hi All,

It will be interesting to see if the trend continues on the share price gaining 5% and then the next day dropping by 5%.

This would give further credibility to the theory that a PII is selling and then re-buying their shares to reduce their average.

Thoughts?

Any thoughts on whether an order is being filled, as any share price gains seem to be managed back down?

I think no matter way we look at it, whilst our trial results were extremely promising, it was however a small trial.

Before any agency or government backs us fully, they would want to see results from a larger trial, hence Pivotal Phase 2.

The ability for Managed Access Programme does change things for SNG and at least allows the drug to be used when no other “approved” options are working.

For Donald Trump, there will always be an America first angle to this and the media will promote the American based products he is taking (even if he does take SNG).

Hi Pmjh,

Worth having a read of the link I posted earlier and perhaps sharing more widely.

It really is an informative article that goes into depth on how a MAP can benefit both patients and a company.

Worth a read for anyone who wants to get their heads around a MAP.

Whilst an older article on the Clinigen website, an informative one none the less:

https://www.clinigengroup.com/insights/2017/supplementing-clinical-development-with-a-managed-access-program/

Great post Joey.

Hopefully the information in the RNS today will help to expedite the peer review and gain interest for the MAP.

Hi All,

Catching up on today’s activities.

Apologies if I have missed this, but does the MAP agreement mean that Synairgen will now be able to recognise some sales for SNG001 in the near future?

Many thanks.

If you go to the below website, set the Journal date to 6850, you can see the current status of the Synairgen patents filed on the 20th and 21st July and published on 2nd September journal.

Interesting that they are at a status of “UK Application Filed” and will still have some way to go e.g “UK applications Published” and “UK Applications Granted”.

https://www.ipo.gov.uk/pro-types/pro-patent/pro-p-os/pro-p-journal/p-pj?startYear=2020&startMonth=September&startDay=2nd+-
+6850&endYear=2020&endMonth=September&endDay=23rd++6853&filter=Synairgen&perPage=10&sort=Publication+Date

It is all speculation but there could be a half year report due by the end of September.

Failing the above, it may be some time in October for an update.

RM did say that they “haven’t announced anything yet” and to be “patient”, so hopefully good things will come to those who wait!

VP

Thanks for posting.

It doesn’t look like it includes SNG001 or any reference to interferon. I think we are also much more advanced than this in our trials.

Ok many thanks. Thought I’d missed something :-)

Well it should hopefully be soon given that the half year report is due!